Division of Respiratory Medicine, BC Children's Hospital, Vancouver, British Columbia, Canada.
Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Pediatr Pulmonol. 2022 Sep;57(9):2244-2251. doi: 10.1002/ppul.25968. Epub 2022 May 21.
Solid-organ transplantation (SOT) has become commonly used in children and is associated with excellent survival rates into adulthood. Data regarding long-term respiratory outcomes following pediatric transplantation are lacking. We aimed to describe the prevalence and nature of respiratory pathology following pediatric heart, kidney, and liver transplant, and identify potential risk factors for respiratory complications.
Retrospective review involving all children under active follow-up at the provincial transplant service in British Columbia, Canada, following SOT.
Of 118 children, 33% experienced respiratory complications, increasing to 54% in heart transplant recipients. Chronic or recurrent cough with persistent chest x-ray changes was the most common clinical picture, and most infections were with nonopportunistic organisms typically found in otherwise healthy children. A history of respiratory illness before transplant was significantly associated with risk of posttransplant respiratory complications. Eight percentage8% were diagnosed with bronchiectasis, which was more common in recipients of heart and kidney transplant. Bronchiectasis was associated with recurrent hospital admissions with lower respiratory tract infections, treatment of acute rejection episodes, and treatment with sirolimus.
Respiratory morbidity is common after pediatric SOT, and bronchiectasis rates were disproportionately high in this patient group. We hypothesize that this relates to recurrent infections resulting from iatrogenic immunosuppression. Direct pulmonary toxicity from immunosuppression drugs may also be contributory. A high index of suspicion for respiratory complications is needed following childhood SOT, particularly in those with a history of respiratory disease before transplant, experiencing recurrent or severe respiratory tract infections, or exposed to intensified immunosuppression.
实体器官移植(SOT)已在儿童中广泛应用,并与成年后极佳的生存率相关。但有关儿童移植后长期呼吸系统结局的数据仍十分有限。我们旨在描述儿科心脏、肾脏和肝脏移植后呼吸系统疾病的流行情况和性质,并确定呼吸系统并发症的潜在危险因素。
这是一项回顾性研究,涉及加拿大不列颠哥伦比亚省省级移植服务机构中正在接受主动随访的所有儿童。
在 118 名儿童中,33%经历了呼吸系统并发症,在心脏移植受者中这一比例增加至 54%。慢性或复发性咳嗽伴持续胸部 X 线改变是最常见的临床表现,大多数感染为非机会性病原体,通常在其他健康儿童中发现。移植前存在呼吸系统疾病史与移植后呼吸系统并发症的风险显著相关。8%被诊断为支气管扩张症,在心脏和肾脏移植受者中更为常见。支气管扩张症与反复下呼吸道感染、急性排斥反应发作的治疗以及西罗莫司的治疗相关。
儿科 SOT 后呼吸系统发病率较高,且该患者群体的支气管扩张症发病率异常高。我们推测这与免疫抑制导致的反复感染有关。免疫抑制药物的直接肺毒性也可能有一定影响。儿童 SOT 后需要高度警惕呼吸系统并发症,尤其是那些在移植前有呼吸系统疾病史、经历反复或严重的呼吸道感染或接受强化免疫抑制治疗的患者。